Combining sodium–glucose co-transporter-2 inhibitor plus glucagon-like peptide-1 receptor agonist for glucose-lowering in type 2 diabetes: effects of drug initiation sequence on kidney function in real-world clinical practice (CombiKid Study)
Hinton W, Joy M, Forbes AK, et al.
Diabetes Obes Metab. Pub. online 16 Jun 2026.
Leggi


